A Randomized, Double-Blind, Phase III Efficacy and Safety Study of PF-00299804 vs. Erlotinib for the treatment of Advanced Non-Small Cell Lung Cancer following Progression after, or intolerance to, at least One Prior Chemotherapy

Grants and Contracts Details

StatusFinished
Effective start/end date12/14/11 → 11/30/16

Funding

  • Pfizer Inc.: $101,318.00